$SIBN
SI-BONE Inc Stock $sibn

$sibn Overview Financials Valuation SEC Filings Company Website

2019 Q1 Form 10-K Financial Statement

#000145983919000011 Filed on March 14, 2019

Income Statement

Concept	2019 Q1	2018	2017 Q4
Revenue	$14.99M	$55.38M	$13.77M
YoY Change	17.93%	15.42%
Cost Of Revenue	$1.526M	$4.833M	$1.220M
YoY Change	45.61%	-5.46%
Gross Profit	$13.47M	$50.55M	$12.55M
YoY Change	15.44%	17.9%
Gross Profit Margin	89.82%	91.27%	91.14%
Selling, General & Admin	$20.58M	$57.14M	$12.91M
YoY Change	53.88%	4.44%
% of Gross Profit	152.85%	113.04%	102.87%
Research & Development	$1.683M	$5.376M	$1.280M
YoY Change	39.55%	-2.49%
% of Gross Profit	12.5%	10.64%	10.2%
Depreciation & Amortization	$193.0K	$722.0K	$190.0K
YoY Change	14.88%	-28.73%	-76.54%
% of Gross Profit	1.43%	1.43%	1.51%
Operating Expenses	$22.26M	$62.51M	$14.19M
YoY Change	52.69%	3.8%
Operating Profit	-$8.799M	-$11.97M	-$1.640M
YoY Change	201.65%	-31.04%
Interest Expense	$1.230M	$5.108M	-$3.220M
YoY Change	-3.53%	-17.67%
% of Operating Profit
Other Income/Expense, Net	-$60.00K	-$1.149M	-$40.00K
YoY Change	-15.49%	-437.94%
Pretax Income	-$9.350M	-$16.84M	-$4.910M
YoY Change	122.62%	-25.89%
Income Tax		$0.00
% Of Pretax Income
Net Earnings	-$9.345M	-$17.45M	-$4.910M
YoY Change	122.45%	-24.25%
Net Earnings / Revenue	-62.34%	-31.51%	-35.66%
Basic Earnings Per Share
Diluted Earnings Per Share	-$383.4K	-$2.195M	-$225.3K
COMMON SHARES
Basic Shares Outstanding	24.46M shares
Diluted Shares Outstanding

Balance Sheet

Concept	2019 Q1	2018	2017 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments	$115.3M	$122.2M
YoY Change		445.54%
Cash & Equivalents	$12.56M	$25.10M	$22.41M
Short-Term Investments	$102.7M	$97.10M
Other Short-Term Assets	$2.200M	$2.000M
YoY Change		53.85%
Inventory	$3.516M	$3.300M	$2.553M
Prepaid Expenses
Receivables	$8.411M	$8.500M	$7.416M
Other Receivables	$0.00	$0.00
Total Short-Term Assets	$129.4M	$136.0M	$33.63M
YoY Change		304.76%
LONG-TERM ASSETS
Property, Plant & Equipment	$2.336M	$2.200M	$1.896M
YoY Change		15.79%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$321.0K	$300.0K	$309.0K
YoY Change		0.0%
Total Long-Term Assets	$2.657M	$2.500M	$2.205M
YoY Change		13.64%
TOTAL ASSETS
Total Short-Term Assets	$129.4M	$136.0M	$33.63M
Total Long-Term Assets	$2.657M	$2.500M	$2.205M
Total Assets	$132.1M	$138.5M	$35.83M
YoY Change		286.87%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$2.811M	$2.100M	$1.814M
YoY Change		16.67%
Accrued Expenses	$7.097M	$6.000M	$5.724M
YoY Change		22.45%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$9.908M	$9.000M	$7.538M
YoY Change		20.0%
LONG-TERM LIABILITIES
Long-Term Debt	$39.03M	$39.00M	$38.70M
YoY Change		-0.26%
Other Long-Term Liabilities	$363.0K	$400.0K	$0.00
YoY Change
Total Long-Term Liabilities	$39.39M	$39.40M	$38.70M
YoY Change		0.77%
TOTAL LIABILITIES
Total Short-Term Liabilities	$9.908M	$9.000M	$7.538M
Total Long-Term Liabilities	$39.39M	$39.40M	$38.70M
Total Liabilities	$49.30M	$48.30M	$46.66M
YoY Change		3.43%
SHAREHOLDERS EQUITY
Retained Earnings	-$166.5M		-$139.7M
YoY Change
Common Stock	$3.000K		$1.000K
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$82.76M	$90.20M	-$129.4M
YoY Change
Total Liabilities & Shareholders Equity	$132.1M	$138.5M	$35.83M
YoY Change		286.87%

Cashflow Statement

Concept	2019 Q1	2018	2017 Q4
OPERATING ACTIVITIES
Net Income	-$9.345M	-$17.45M	-$4.910M
YoY Change	122.45%	-24.25%
Depreciation, Depletion And Amortization	$193.0K	$722.0K	$190.0K
YoY Change	14.88%	-28.73%	-76.54%
Cash From Operating Activities	-$7.078M	-$14.52M	-$4.040M
YoY Change	60.46%	-17.18%	-64.96%
INVESTING ACTIVITIES
Capital Expenditures	$412.0K	$942.0K	-$110.0K
YoY Change	88.99%	97.07%	-71.05%
Acquisitions
YoY Change
Other Investing Activities	-$5.140M	-$96.88M
YoY Change
Cash From Investing Activities	-$5.553M	-$97.83M	-$110.0K
YoY Change	2447.25%	20365.48%	-71.05%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net	$0.00	$73.00K
YoY Change
Debt Paid & Issued, Net		$0.00
YoY Change		-100.0%
Cash From Financing Activities	$125.0K	$115.2M	8.550M
YoY Change	525.0%	795.27%	-65.22%
NET CHANGE
Cash From Operating Activities	-$7.078M	-$14.52M	-4.040M
Cash From Investing Activities	-$5.553M	-$97.83M	-110.0K
Cash From Financing Activities	$125.0K	$115.2M	8.550M
Net Change In Cash	-$12.56M	$2.712M	4.400M
YoY Change	172.08%	-152.7%	-65.27%
FREE CASH FLOW
Cash From Operating Activities	-$7.078M	-$14.52M	-$4.040M
Capital Expenditures	$412.0K	$942.0K	-$110.0K
Free Cash Flow	-$7.490M	-$15.46M	-$3.930M
YoY Change	61.81%	-14.14%	-64.75%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2018	dei	Amendment Flag AmendmentFlag	false
CY2018	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2018	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2018	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2018
CY2018	dei	Document Period End Date DocumentPeriodEndDate	2018-12-31
CY2018	dei	Document Type DocumentType	10-K
CY2018	dei	Entity Central Index Key EntityCentralIndexKey	0001459839
CY2019Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	24458938	shares
CY2018	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2018	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	true
CY2018	dei	Entity Ex Transition Period EntityExTransitionPeriod	false
CY2018	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2018Q2	dei	Entity Public Float EntityPublicFloat	0	USD
CY2018	dei	Entity Registrant Name EntityRegistrantName	SI-BONE, INC.
CY2018	dei	Entity Shell Company EntityShellCompany	false
CY2018	dei	Entity Small Business EntitySmallBusiness	true
CY2018	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2018	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2017	sibn	Adjustmentsto Additional Paidin Capital Sharebased Compensation Vesting Of Early Exercised Stock Options AdjustmentstoAdditionalPaidinCapitalSharebasedCompensationVestingOfEarlyExercisedStockOptions	122000	USD
CY2018	sibn	Adjustmentsto Additional Paidin Capital Sharebased Compensation Vesting Of Early Exercised Stock Options AdjustmentstoAdditionalPaidinCapitalSharebasedCompensationVestingOfEarlyExercisedStockOptions	139000	USD
CY2018	sibn	Adjustmentsto Additional Paidin Capital Warrant Converted AdjustmentstoAdditionalPaidinCapitalWarrantConverted	1248000	USD
CY2017Q4	sibn	Common Stock Equivalent Shares Stock Options Outstanding CommonStockEquivalentSharesStockOptionsOutstanding	3001929	shares
CY2017	sibn	Common Stock Series Two Number Of Directors Entitled To Elect CommonStockSeriesTwoNumberOfDirectorsEntitledToElect	2	director
CY2017Q4	sibn	Convertible Preferred Stock Minimum Public Offering For Conversion ConvertiblePreferredStockMinimumPublicOfferingForConversion	50000000	USD
CY2017Q4	sibn	Convertible Preferred Stock Minimum Public Offering Per Share For Conversion ConvertiblePreferredStockMinimumPublicOfferingPerShareForConversion	30.0996
CY2018Q4	sibn	Debt Instrument Covenant Minimum Cash Balance DebtInstrumentCovenantMinimumCashBalance	5000000	USD
CY2017	sibn	Deferred Income Tax Expense Benefit Net Of Valuation Allowance DeferredIncomeTaxExpenseBenefitNetOfValuationAllowance	0	USD
CY2018	sibn	Deferred Income Tax Expense Benefit Net Of Valuation Allowance DeferredIncomeTaxExpenseBenefitNetOfValuationAllowance	0	USD
CY2017Q4	sibn	Deferred Tax Assets Depreciation And Amortization DeferredTaxAssetsDepreciationAndAmortization	179000	USD
CY2018Q4	sibn	Deferred Tax Assets Depreciation And Amortization DeferredTaxAssetsDepreciationAndAmortization	132000	USD
CY2017Q4	sibn	Equity And Temporary Equity Common Stock Equivalent Shares Issued And Reserved For Future Issuance EquityAndTemporaryEquityCommonStockEquivalentSharesIssuedAndReservedForFutureIssuance	18986360	shares
CY2017Q4	sibn	Equity And Temporary Equity Shares Issued And Reserved For Future Issuance EquityAndTemporaryEquitySharesIssuedAndReservedForFutureIssuance	18787177	shares
CY2018Q4	sibn	Equity And Temporary Equity Shares Issued And Reserved For Future Issuance EquityAndTemporaryEquitySharesIssuedAndReservedForFutureIssuance	29760595	shares
CY2018	sibn	Increase Decrease In Net Deferred Tax Asset Position Change In Enacted Tax Rate IncreaseDecreaseInNetDeferredTaxAssetPositionChangeInEnactedTaxRate	-15800000	USD
CY2017	sibn	Initial Public Offering Costs Incurred But Not Yet Paid InitialPublicOfferingCostsIncurredButNotYetPaid	0	USD
CY2018	sibn	Initial Public Offering Costs Incurred But Not Yet Paid InitialPublicOfferingCostsIncurredButNotYetPaid	7000	USD
CY2017Q4	sibn	Liability For Early Exercise Of Options Current LiabilityForEarlyExerciseOfOptionsCurrent	100000	USD
CY2017Q4	sibn	Liability For Early Exercise Of Options Current LiabilityForEarlyExerciseOfOptionsCurrent	65000	USD
CY2018Q4	sibn	Liability For Early Exercise Of Options Current LiabilityForEarlyExerciseOfOptionsCurrent	300000	USD
CY2018Q4	sibn	Liability For Early Exercise Of Options Current LiabilityForEarlyExerciseOfOptionsCurrent	331000	USD
CY2018Q4	sibn	Marketable Securities Accumulated Gross Unrealized Gain Before Tax MarketableSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	17000	USD
CY2018Q4	sibn	Marketable Securities Accumulated Gross Unrealized Loss Before Tax MarketableSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	7000	USD
CY2018Q4	sibn	Marketable Securities Amortized Cost MarketableSecuritiesAmortizedCost	119951000	USD
CY2018Q4	sibn	Marketable Securities Fair Value MarketableSecuritiesFairValue	119961000	USD
CY2017	sibn	Net Exerciseof Common Warrants NetExerciseofCommonWarrants	0	USD
CY2018	sibn	Net Exerciseof Common Warrants NetExerciseofCommonWarrants	1248000	USD
CY2017	sibn	Notes Receivable Forgiveness NotesReceivableForgiveness	400000	USD
CY2018	sibn	Notes Receivable Forgiveness NotesReceivableForgiveness	0	USD
CY2017Q4	sibn	Offering Costs Expensed OfferingCostsExpensed	1300000	USD
CY2017	sibn	Offering Costs Expensed OfferingCostsExpensed	1300000	USD
CY2018Q4	sibn	Operating Loss Carryforwards Limited OperatingLossCarryforwardsLimited	1400000	USD
CY2017Q4	sibn	Preferred Stock Warrant Liability PreferredStockWarrantLiability	422000	USD
CY2018Q4	sibn	Preferred Stock Warrant Liability PreferredStockWarrantLiability	0	USD
CY2017Q4	sibn	Sales And Product Warranty Accrual Current SalesAndProductWarrantyAccrualCurrent	149000	USD
CY2018Q4	sibn	Sales And Product Warranty Accrual Current SalesAndProductWarrantyAccrualCurrent	35000	USD
CY2018	sibn	Sales Credit Reserve Period SalesCreditReservePeriod	P1Y
CY2017Q4	sibn	Share Based Compensation Arrangement By Share Based Payment Award Options Early Exercise Common Stock Subject To Repurchase ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsEarlyExerciseCommonStockSubjectToRepurchase	16117	shares
CY2018Q4	sibn	Share Based Compensation Arrangement By Share Based Payment Award Options Early Exercise Common Stock Subject To Repurchase ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsEarlyExerciseCommonStockSubjectToRepurchase	74019	shares
CY2018	sibn	Standard Product Warranty Term StandardProductWarrantyTerm	P1Y
CY2017	sibn	Stock Issued During Period Value Unvested Stock Options Exercised StockIssuedDuringPeriodValueUnvestedStockOptionsExercised	0	USD
CY2018	sibn	Stock Issued During Period Value Unvested Stock Options Exercised StockIssuedDuringPeriodValueUnvestedStockOptionsExercised	0	USD
CY2018	sibn	Stock Issued During Period Value Warrants Exercised StockIssuedDuringPeriodValueWarrantsExercised	0	USD
CY2018	sibn	Stock Repurchased During Period Originally Issued For Exercise Of Unvested Stock Options Value StockRepurchasedDuringPeriodOriginallyIssuedForExerciseOfUnvestedStockOptionsValue	0	USD
CY2017	sibn	Stockholders Equity Receivable From Officers And Directors For Issuance Of Capital Stock Forgiveness Of Debt StockholdersEquityReceivableFromOfficersAndDirectorsForIssuanceOfCapitalStockForgivenessOfDebt	437000	USD
CY2017	sibn	Stockholders Equity Receivable From Officers And Directors For Issuance Of Capital Stock Payment Received StockholdersEquityReceivableFromOfficersAndDirectorsForIssuanceOfCapitalStockPaymentReceived	84000	USD
CY2018	sibn	Temporary Equity Conversion Of Temporary Equity To Equity Shares TemporaryEquityConversionOfTemporaryEquityToEquityShares	11871578	shares
CY2018	sibn	Temporary Equity Conversion Of Temporary Equity To Equity Value TemporaryEquityConversionOfTemporaryEquityToEquityValue	118548000	USD
CY2017Q4	sibn	Temporary Equity Shareholder Approval Minimum Shares Outstanding TemporaryEquityShareholderApprovalMinimumSharesOutstanding	277778	shares
CY2017	sibn	Temporary Equity Stock Issued During Period Shares New Issues TemporaryEquityStockIssuedDuringPeriodSharesNewIssues	540874	shares
CY2017	sibn	Vesting Of Early Exercised Stock Options VestingOfEarlyExercisedStockOptions	122000	USD
CY2018	sibn	Vesting Of Early Exercised Stock Options VestingOfEarlyExercisedStockOptions	139000	USD
CY2017	sibn	Write Off Of Debt Discount WriteOffOfDebtDiscount	650000	USD
CY2018	sibn	Write Off Of Debt Discount WriteOffOfDebtDiscount	0	USD
CY2017	sibn	Write Off Of Initial Public Offering Costs WriteOffOfInitialPublicOfferingCosts	1292000	USD
CY2018	sibn	Write Off Of Initial Public Offering Costs WriteOffOfInitialPublicOfferingCosts	0	USD
CY2017Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	1814000	USD
CY2018Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	2146000	USD
CY2017Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	7416000	USD
CY2018Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	8486000	USD
CY2017	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	0	USD
CY2018	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	209000	USD
CY2017Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	5724000	USD
CY2018Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	6860000	USD
CY2017Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	341000	USD
CY2018Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	583000	USD
CY2017Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	3022000	USD
CY2018Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	3364000	USD
CY2017Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	402000	USD
CY2018Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	439000	USD
CY2017Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	9943000	USD
CY2018Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	246927000	USD
CY2017	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	1438000	USD
CY2018	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	2312000	USD
CY2018	us-gaap	Adjustments To Additional Paid In Capital Stock Issued Issuance Costs AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts	1900000	USD
CY2018Q4	us-gaap	Adjustments To Additional Paid In Capital Warrant Issued AdjustmentsToAdditionalPaidInCapitalWarrantIssued	1200000	USD
CY2017	us-gaap	Advertising Expense AdvertisingExpense	800000	USD
CY2018	us-gaap	Advertising Expense AdvertisingExpense	700000	USD
CY2017Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	268000	USD
CY2018Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	263000	USD
CY2017	us-gaap	Allowance For Doubtful Accounts Receivable Recoveries AllowanceForDoubtfulAccountsReceivableRecoveries	36000	USD
CY2018	us-gaap	Allowance For Doubtful Accounts Receivable Recoveries AllowanceForDoubtfulAccountsReceivableRecoveries	5000	USD
CY2017	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	285000	USD
CY2018	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	259000	USD
CY2017Q4	us-gaap	Assets Assets	35834000	USD
CY2018Q4	us-gaap	Assets Assets	138521000	USD
CY2017Q4	us-gaap	Assets Current AssetsCurrent	33629000	USD
CY2018Q4	us-gaap	Assets Current AssetsCurrent	136042000	USD
CY2018Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	17000	USD
CY2018Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	7000	USD
CY2018Q4	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	97093000	USD
CY2017Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	0	USD
CY2018Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	97103000	USD
CY2017	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	97000	USD
CY2018	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	82000	USD
CY2016Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	27900000	USD
CY2017Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	22408000	USD
CY2018Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	25120000	USD
CY2017	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-5492000	USD
CY2018	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	2712000	USD
CY2018Q4	us-gaap	Cash Equivalents At Carrying Value CashEquivalentsAtCarryingValue	22858000	USD
CY2017Q4	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights	280876	shares
CY2017Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2018Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2017	us-gaap	Common Stock Dividends Per Share Declared CommonStockDividendsPerShareDeclared	0
CY2018	us-gaap	Common Stock Dividends Per Share Declared CommonStockDividendsPerShareDeclared	0
CY2017Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2017Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2018Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2018Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2017Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	19333333	shares
CY2017Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	19333333	shares
CY2018Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2018Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2017Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	3603140	shares
CY2018Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	24450757	shares
CY2017Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	3603140	shares
CY2018Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	24450757	shares
CY2017Q4	us-gaap	Common Stock Value CommonStockValue	1000	USD
CY2018Q4	us-gaap	Common Stock Value CommonStockValue	3000	USD
CY2017	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-23109000	USD
CY2018	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-17416000	USD
CY2017	us-gaap	Conversion Of Stock Amount Converted1 ConversionOfStockAmountConverted1	0	USD
CY2018	us-gaap	Conversion Of Stock Amount Converted1 ConversionOfStockAmountConverted1	118547000	USD
CY2017	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	5112000	USD
CY2018	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	4833000	USD
CY2017	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	0	USD
CY2018	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	0	USD
CY2017	us-gaap	Current Foreign Tax Expense Benefit CurrentForeignTaxExpenseBenefit	0	USD
CY2018	us-gaap	Current Foreign Tax Expense Benefit CurrentForeignTaxExpenseBenefit	0	USD
CY2017	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	0	USD
CY2018	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	0	USD
CY2017	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	0	USD
CY2018	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	0	USD
CY2018Q4	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount	40000000	USD
CY2017	us-gaap	Debt Instrument Decrease Forgiveness DebtInstrumentDecreaseForgiveness	437000	USD
CY2018	us-gaap	Debt Instrument Decrease Forgiveness DebtInstrumentDecreaseForgiveness	0	USD
CY2017	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	-9574000	USD
CY2018	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	3555000	USD
CY2018Q4	us-gaap	Deferred Finance Costs Net DeferredFinanceCostsNet	1037000	USD
CY2017	us-gaap	Deferred Foreign Income Tax Expense Benefit DeferredForeignIncomeTaxExpenseBenefit	0	USD
CY2018	us-gaap	Deferred Foreign Income Tax Expense Benefit DeferredForeignIncomeTaxExpenseBenefit	200000	USD
CY2017	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-7513000	USD
CY2018	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	4577000	USD
CY2017Q4	us-gaap	Deferred Offering Costs DeferredOfferingCosts	0	USD
CY2018Q4	us-gaap	Deferred Offering Costs DeferredOfferingCosts	0	USD
CY2017	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	2061000	USD
CY2018	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	822000	USD
CY2017Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	35835000	USD
CY2018Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	40412000	USD
CY2017Q4	us-gaap	Deferred Tax Assets In Process Research And Development DeferredTaxAssetsInProcessResearchAndDevelopment	2070000	USD
CY2018Q4	us-gaap	Deferred Tax Assets In Process Research And Development DeferredTaxAssetsInProcessResearchAndDevelopment	2255000	USD
CY2017Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	0	USD
CY2018Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	0	USD
CY2017Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	32210000	USD
CY2018Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	35067000	USD
CY2017Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals	1376000	USD
CY2018Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals	2958000	USD
CY2016Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	43348000	USD
CY2017Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	35835000	USD
CY2018Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	40412000	USD
CY2017	us-gaap	Depreciation Depreciation	1000000	USD
CY2018	us-gaap	Depreciation Depreciation	700000	USD
CY2017	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	1013000	USD
CY2018	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	722000	USD
CY2017	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-6.65
CY2018	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-2.20
CY2017	us-gaap	Effect Of Exchange Rate On Cash And Cash Equivalents EffectOfExchangeRateOnCashAndCashEquivalents	-346000	USD
CY2018	us-gaap	Effect Of Exchange Rate On Cash And Cash Equivalents EffectOfExchangeRateOnCashAndCashEquivalents	-94000	USD
CY2018	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.000
CY2017	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.34
CY2017Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	0	USD
CY2018Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	360000	USD
CY2017	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	340000	USD
CY2018	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.21
CY2017	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	0.326
CY2018	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.262
CY2018Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	5425000	USD
CY2018Q4	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized	4500000	USD
CY2018	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P2Y3M15D
CY2017	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-166000	USD
CY2018	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	826000	USD
CY2018	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Gain Loss Included In Earnings FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings	826000	USD
CY2017	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.000
CY2017	us-gaap	Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate	-0.687
CY2018	us-gaap	Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate	0.000
CY2018	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Settlements FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements	1248000	USD
CY2017Q4	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue	422000	USD
CY2018Q4	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue	0	USD
CY2017	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	-214000	USD
CY2017	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	-0.025
CY2018	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	-0.008
CY2017	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.043
CY2018	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.053
CY2017	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits EffectiveIncomeTaxRateReconciliationTaxCredits	-0.003
CY2018	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits EffectiveIncomeTaxRateReconciliationTaxCredits	-0.007
CY2017Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	3732000	USD
CY2018	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	-52000	USD
CY2017	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	13062000	USD
CY2018	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	12639000	USD
CY2017	us-gaap	Gross Profit GrossProfit	42871000	USD
CY2018	us-gaap	Gross Profit GrossProfit	50547000	USD
CY2017	us-gaap	Impairment Of Long Lived Assets Held For Use ImpairmentOfLongLivedAssetsHeldForUse	0	USD
CY2018	us-gaap	Impairment Of Long Lived Assets Held For Use ImpairmentOfLongLivedAssetsHeldForUse	0	USD
CY2017	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	-22717000	USD
CY2018	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	-16835000	USD
CY2017	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	-322000	USD
CY2018	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	-618000	USD
CY2017	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-23039000	USD
CY2018	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-17453000	USD
CY2017	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
CY2018	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
CY2017	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	811000	USD
CY2018	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	251000	USD
CY2017	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	1313000	USD
CY2018	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	1023000	USD
CY2017	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	1792000	USD
CY2018	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	1260000	USD
CY2017	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	980000	USD
CY2018	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	759000	USD
CY2017	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-72000	USD
CY2018	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	752000	USD
CY2017	us-gaap	Interest Expense InterestExpense	6204000	USD
CY2018	us-gaap	Interest Expense InterestExpense	5108000	USD
CY2017	us-gaap	Interest Paid Net InterestPaidNet	4514000	USD
CY2018Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-157177000	USD
CY2018Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-157200000	USD
CY2017	us-gaap	Revenues Revenues	47983000	USD
CY2018	us-gaap	Revenues Revenues	55380000	USD
CY2017Q4	us-gaap	Sales And Excise Tax Payable Current SalesAndExciseTaxPayableCurrent	466000	USD
CY2018Q4	us-gaap	Sales And Excise Tax Payable Current SalesAndExciseTaxPayableCurrent	388000	USD
CY2018	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-97825000	USD
CY2017	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-17530000	USD
CY2018	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-14519000	USD
CY2018	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-14500000	USD
CY2017	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	41646000	USD
CY2018	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	44497000	USD
CY2017	us-gaap	Share Based Compensation ShareBasedCompensation	1438000	USD
CY2018	us-gaap	Share Based Compensation ShareBasedCompensation	2312000	USD
CY2017Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant	29654	shares
CY2017Q4	us-gaap	Long Term Debt LongTermDebt	38700000	USD
CY2018Q4	us-gaap	Long Term Debt LongTermDebt	38963000	USD
CY2018Q4	us-gaap	Long Term Debt LongTermDebt	39000000	USD
CY2018Q4	us-gaap	Long Term Debt Maturities Repayments Of Principal In Next Twelve Months LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths	0	USD
CY2017	us-gaap	Net Income Loss NetIncomeLoss	-23039000	USD
CY2018	us-gaap	Net Income Loss NetIncomeLoss	-17453000	USD
CY2018	us-gaap	Interest Paid Net InterestPaidNet	5500000	USD
CY2017Q4	us-gaap	Interest Payable Current InterestPayableCurrent	831000	USD
CY2018Q4	us-gaap	Interest Payable Current InterestPayableCurrent	0	USD
CY2017Q4	us-gaap	Inventory Net InventoryNet	2553000	USD
CY2018Q4	us-gaap	Inventory Net InventoryNet	3343000	USD
CY2018	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1	segment
CY2018	us-gaap	Number Of Reportable Segments NumberOfReportableSegments	1	segment
CY2017	us-gaap	Operating Expenses OperatingExpenses	60221000	USD
CY2018	us-gaap	Operating Expenses OperatingExpenses	62512000	USD
CY2017	us-gaap	Operating Income Loss OperatingIncomeLoss	-17350000	USD
CY2017	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	0	USD
CY2018	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	10000	USD
CY2017	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	-70000	USD
CY2018	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	27000	USD
CY2017	us-gaap	Investment Income Interest InvestmentIncomeInterest	175000	USD
CY2018	us-gaap	Investment Income Interest InvestmentIncomeInterest	769000	USD
CY2017Q4	us-gaap	Liabilities Liabilities	46664000	USD
CY2018Q4	us-gaap	Liabilities Liabilities	48329000	USD
CY2017Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	35834000	USD
CY2018Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	138521000	USD
CY2017Q4	us-gaap	Liabilities Current LiabilitiesCurrent	7538000	USD
CY2018Q4	us-gaap	Liabilities Current LiabilitiesCurrent	9006000	USD
CY2018Q4	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Four LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour	17778000	USD
CY2018Q4	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Three LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree	17778000	USD
CY2018Q4	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Two LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo	4444000	USD
CY2017Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	38704000	USD
CY2018Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	38963000	USD
CY2017	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	12862000	USD
CY2018	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	115150000	USD
CY2017	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-478000	USD
CY2018	us-gaap	Operating Income Loss OperatingIncomeLoss	-11965000	USD
CY2018Q4	us-gaap	Operating Leases Future Minimum Payments Due OperatingLeasesFutureMinimumPaymentsDue	5852000	USD
CY2018Q4	us-gaap	Operating Leases Future Minimum Payments Due In Five Years OperatingLeasesFutureMinimumPaymentsDueInFiveYears	844000	USD
CY2018Q4	us-gaap	Operating Leases Future Minimum Payments Due In Four Years OperatingLeasesFutureMinimumPaymentsDueInFourYears	842000	USD
CY2018Q4	us-gaap	Operating Leases Future Minimum Payments Due In Three Years OperatingLeasesFutureMinimumPaymentsDueInThreeYears	914000	USD
CY2018Q4	us-gaap	Operating Leases Future Minimum Payments Due In Two Years OperatingLeasesFutureMinimumPaymentsDueInTwoYears	1033000	USD
CY2018Q4	us-gaap	Operating Leases Future Minimum Payments Due Thereafter OperatingLeasesFutureMinimumPaymentsDueThereafter	1184000	USD
CY2018Q4	us-gaap	Operating Leases Future Minimum Payments Receivable Current OperatingLeasesFutureMinimumPaymentsReceivableCurrent	1035000	USD
CY2017	us-gaap	Operating Leases Rent Expense Net OperatingLeasesRentExpenseNet	1000000	USD
CY2018	us-gaap	Operating Leases Rent Expense Net OperatingLeasesRentExpenseNet	1200000	USD
CY2017Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	140000	USD
CY2018Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	98000	USD
CY2017Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	309000	USD
CY2018Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	325000	USD
CY2017	us-gaap	Proceeds From Issuance Initial Public Offering ProceedsFromIssuanceInitialPublicOffering	0	USD
CY2018	us-gaap	Proceeds From Issuance Initial Public Offering ProceedsFromIssuanceInitialPublicOffering	115506000	USD
CY2017	us-gaap	Proceeds From Issuance Of Long Term Debt ProceedsFromIssuanceOfLongTermDebt	40000000	USD
CY2018	us-gaap	Proceeds From Issuance Of Long Term Debt ProceedsFromIssuanceOfLongTermDebt	0	USD
CY2017	us-gaap	Proceeds From Issuance Of Redeemable Preferred Stock ProceedsFromIssuanceOfRedeemablePreferredStock	5427000	USD
CY2018	us-gaap	Proceeds From Issuance Of Redeemable Preferred Stock ProceedsFromIssuanceOfRedeemablePreferredStock	0	USD
CY2017	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	383000	USD
CY2018	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	1614000	USD
CY2018	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-1149000	USD
CY2017	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	0	USD
CY2018	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	73000	USD
CY2017	us-gaap	Payments Of Debt Extinguishment Costs PaymentsOfDebtExtinguishmentCosts	29081000	USD
CY2018	us-gaap	Payments Of Debt Extinguishment Costs PaymentsOfDebtExtinguishmentCosts	0	USD
CY2017	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	1540000	USD
CY2018	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	0	USD
CY2017	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	1292000	USD
CY2018	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	1897000	USD
CY2017	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	0	USD
CY2018	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	96883000	USD
CY2017	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	478000	USD
CY2018	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	942000	USD
CY2017	us-gaap	Preferred Stock Dividends Per Share Declared PreferredStockDividendsPerShareDeclared	0
CY2018	us-gaap	Preferred Stock Dividends Per Share Declared PreferredStockDividendsPerShareDeclared	0
CY2018Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2018Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2018Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2018Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2018Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2018Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2017Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2018Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2017Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	1252000	USD
CY2018Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	1990000	USD
CY2017Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	4918000	USD
CY2018Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	5518000	USD
CY2017Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1896000	USD
CY2018Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	2154000	USD
CY2017Q4	us-gaap	Purchase Obligation PurchaseObligation	100000	USD
CY2018Q4	us-gaap	Purchase Obligation PurchaseObligation	200000	USD
CY2017	us-gaap	Repayment Of Notes Receivable From Related Parties RepaymentOfNotesReceivableFromRelatedParties	84000	USD
CY2018	us-gaap	Repayment Of Notes Receivable From Related Parties RepaymentOfNotesReceivableFromRelatedParties	0	USD
CY2017	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	1119000	USD
CY2018	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	0	USD
CY2017	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	5513000	USD
CY2018	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	5376000	USD
CY2017Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-139724000	USD
CY2018Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant	2497082	shares
CY2018	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod	65694	shares
CY2018	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	100080	shares
CY2017	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	1.80
CY2018	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	3.98
CY2017Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	3585000	USD
CY2018Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	43905000	USD
CY2017Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	3001929	shares
CY2018Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	2641198	shares
CY2017Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	4.15
CY2018Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	4.27
CY2018Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue	41882000	USD
CY2018Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber	1762687	shares
CY2018Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice	3.73
CY2018Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue	40154000	USD
CY2018Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber	2366723	shares
CY2018Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice	4.14
CY2018	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	4.08
CY2018	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice	4.81
CY2018	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	8.88
CY2018	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P6Y7M6D
CY2018	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1	P5Y11M8D
CY2018	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1	P6Y5M27D
CY2018Q4	us-gaap	Stock Issued During Period Shares Conversion Of Convertible Securities StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities	12066654	shares
CY2018	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	395117	shares
CY2018	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	118548000	USD
CY2018	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	113603000	USD
CY2017	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	383000	USD
CY2018	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	1136000	USD
CY2016Q4	us-gaap	Stockholders Equity StockholdersEquity	-108733000	USD
CY2017Q4	us-gaap	Stockholders Equity StockholdersEquity	-129378000	USD
CY2018Q4	us-gaap	Stockholders Equity StockholdersEquity	90192000	USD
CY2018Q4	us-gaap	Stockholders Equity Note Stock Split Conversion Ratio1 StockholdersEquityNoteStockSplitConversionRatio1	0.0556
CY2018Q4	us-gaap	Stockholders Equity Note Stock Split Conversion Ratio1 StockholdersEquityNoteStockSplitConversionRatio1	0.0556
CY2016Q4	us-gaap	Temporary Equity Carrying Amount Attributable To Parent TemporaryEquityCarryingAmountAttributableToParent	113121000	USD
CY2017Q4	us-gaap	Temporary Equity Carrying Amount Attributable To Parent TemporaryEquityCarryingAmountAttributableToParent	118548000	USD
CY2018Q4	us-gaap	Temporary Equity Carrying Amount Attributable To Parent TemporaryEquityCarryingAmountAttributableToParent	0	USD
CY2017Q4	us-gaap	Temporary Equity Liquidation Preference TemporaryEquityLiquidationPreference	119194000	USD
CY2018Q4	us-gaap	Temporary Equity Liquidation Preference TemporaryEquityLiquidationPreference	0	USD
CY2017Q4	us-gaap	Temporary Equity Par Or Stated Value Per Share TemporaryEquityParOrStatedValuePerShare	0.0001
CY2018Q4	us-gaap	Temporary Equity Par Or Stated Value Per Share TemporaryEquityParOrStatedValuePerShare	0.0001
CY2017Q4	us-gaap	Temporary Equity Shares Authorized TemporaryEquitySharesAuthorized	12104749	shares
CY2018Q4	us-gaap	Temporary Equity Shares Authorized TemporaryEquitySharesAuthorized	0	shares
CY2017Q4	us-gaap	Temporary Equity Shares Issued TemporaryEquitySharesIssued	11871578	shares
CY2018Q4	us-gaap	Temporary Equity Shares Issued TemporaryEquitySharesIssued	0	shares
CY2016Q4	us-gaap	Temporary Equity Shares Outstanding TemporaryEquitySharesOutstanding	11330704	shares
CY2017Q4	us-gaap	Temporary Equity Shares Outstanding TemporaryEquitySharesOutstanding	11871578	shares
CY2018Q4	us-gaap	Temporary Equity Shares Outstanding TemporaryEquitySharesOutstanding	0	shares
CY2017	us-gaap	Temporary Equity Stock Issued During Period Value New Issues TemporaryEquityStockIssuedDuringPeriodValueNewIssues	5427000	USD
CY2016Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	950000	USD
CY2017Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	993000	USD
CY2018Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	1084000	USD
CY2017	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	43000	USD
CY2018	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	91000	USD
CY2017Q4	us-gaap	Unrecognized Tax Benefits Interest On Income Taxes Accrued UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued	0	USD
CY2018Q4	us-gaap	Unrecognized Tax Benefits Interest On Income Taxes Accrued UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued	0	USD
CY2017	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	-7513000	USD
CY2018	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	4577000	USD
CY2017	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	3467096	shares
CY2018	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	7950284	shares
CY2018	us-gaap	Advertising Cost Policy Expensed Advertising Cost AdvertisingCostPolicyExpensedAdvertisingCost	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Advertising Expenditures</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The cost of advertising is included in Sales and Marketing expense in the consolidated financial statements and expensed as incurred.</font></div></div>
CY2018	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Concentration of Credit Risk </font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Financial instruments that potentially subject the Company to a concentration of credit risk consist of cash and cash equivalents. The Company’s cash and cash equivalents are deposited with financial institutions in the United States and in Europe; the majority of the Company’s cash and cash equivalents are deposited with a single financial institution in the United States. Deposits in this institution exceed the amount of insurance provided on such deposits. The Company has not experienced any losses on its deposits of cash and cash equivalents.</font></div></div>
CY2018	us-gaap	Nature Of Operations NatureOfOperations	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">The Company and Nature of Business</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">SI-BONE, Inc. (the “Company”) was incorporated in the state of Delaware on March 18, 2008 and is headquartered in Santa Clara, California. The Company is a medical device company that has pioneered a proprietary minimally invasive surgical implant system to fuse the sacroiliac joint for treatment of the most common types of sacroiliac joint disorders that cause lower back pain. The Company introduced its iFuse Implant System, or iFuse, in 2009 in the United States, in 2010 in certain countries in the European Union, and in 2015 in certain countries in the rest of the world.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Reverse Stock Split</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In October 2018, the Company's board of directors and stockholders approved a 1-for-18 reverse stock split of the Company's common stock and redeemable convertible preferred stock, which was effected on October 4, 2018. The par value of the common stock and redeemable convertible preferred stock was not adjusted as a result of the reverse split. All issued and outstanding share and per share amounts of common stock, redeemable convertible preferred stock, stock options, and warrants included in the accompanying consolidated financial statements have been adjusted to reflect this reverse stock split for all periods presented.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Initial Public Offering </font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On October 16, 2018, the Company’s Registration Statement on Form S-1 (File No. 333-227445) relating to the initial public offering (IPO) of its common stock was declared effective by the Securities and Exchange Commission (SEC). Pursuant to such Registration Statement, the Company sold </font><font style="font-family:inherit;font-size:10pt;">8,280,000</font><font style="font-family:inherit;font-size:10pt;"> shares at an initial public offering price of </font><font style="font-family:inherit;font-size:10pt;">$15.00</font><font style="font-family:inherit;font-size:10pt;"> per share for net proceeds of </font><font style="font-family:inherit;font-size:10pt;">$113.6 million</font><font style="font-family:inherit;font-size:10pt;"> to the Company, net of underwriting discounts and commissions and offering costs. </font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In connection with the IPO, the Company's outstanding shares of redeemable convertible preferred stock were automatically converted into an aggregate of </font><font style="font-family:inherit;font-size:10pt;">12,066,654</font><font style="font-family:inherit;font-size:10pt;"> shares of common stock, and the Company's outstanding warrants to purchase </font><font style="font-family:inherit;font-size:10pt;">156,550</font><font style="font-family:inherit;font-size:10pt;"> shares of redeemable convertible preferred stock were automatically converted into warrants to purchase an aggregate of </font><font style="font-family:inherit;font-size:10pt;">160,657</font><font style="font-family:inherit;font-size:10pt;"> shares of common stock, resulting in reclassification of the related redeemable convertible preferred stock warrant liability of </font><font style="font-family:inherit;font-size:10pt;">$1.2 million</font><font style="font-family:inherit;font-size:10pt;"> in additional paid-in-capital.</font></div></div>
CY2018	us-gaap	Revenue Recognition Sales Of Goods RevenueRecognitionSalesOfGoods	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Revenue Recognition</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company’s revenue is derived from the sale of its products to medical groups and hospitals through its direct sales force and distributors throughout the United States and Europe.</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In accordance with ASC Topic 605, Revenue Recognition (“ASC 605”), the Company recognizes revenue when persuasive evidence of an arrangement exists, title and risk of loss has transferred to the customer, the sales price is fixed or determinable, and collectability is reasonably assured. For the majority of product sales where the Company’s sales representative delivers the product at the point of implantation at hospitals or other medical facilities, the Company recognizes revenue related to product sales upon completion of the procedure and authorization by the customer. Revenue is recognized upon receipt of a purchase agreement or agreement on pricing terms with the customer and when all other revenue recognition criteria are met. For the remaining sales, which include distributor and hospital sales where the product is ordered in advance of a procedure and a valid purchase order has been received, the Company recognizes revenue based upon shipping or delivery terms, which represents the point in time when the customer has taken ownership and assumed risk of loss and the required revenue recognition criteria are met. Such customers are obligated to pay within specified terms regardless of when or if they ever sell or use the products, and the Company has no post-delivery obligations.</font></div></div>
CY2018	us-gaap	Use Of Estimates UseOfEstimates	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Use of Estimates </font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Significant accounting estimates and management judgments reflected in the consolidated financial statements include: fair value of assets and liabilities; analysis of the allowance for doubtful accounts; inventory valuation; valuation of deferred tax assets, including related valuation allowances; fair value of common stock and redeemable convertible preferred stock warrants; stock-based compensation; and useful lives of long-lived assets. Estimates are based on historical experience, where applicable and other assumptions believed to be reasonable by the management. Actual results could differ from those estimates.</font></div></div>

Files In Submission

Name	View Source	Status
0001459839-19-000011-index-headers.html	Edgar Link	pending
0001459839-19-000011-index.html	Edgar Link	pending
0001459839-19-000011.txt	Edgar Link	pending
0001459839-19-000011-xbrl.zip	Edgar Link	pending
doc193009209v1sibonef_image1.jpg	Edgar Link	pending
doc193009209v1sibonef_image2.jpg	Edgar Link	pending
doc193009209v1sibonef_image3.jpg	Edgar Link	pending
doc193009209v1sibone_image10.jpg	Edgar Link	pending
doc193009209v1sibone_image11.jpg	Edgar Link	pending
feb2019siboneodiimia1yr.jpg	Edgar Link	pending
feb2019sibonevasimia1yr.jpg	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
item1image1.jpg	Edgar Link	pending
item1image2.jpg	Edgar Link	pending
item1image3.jpg	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R71.htm	Edgar Link	pending
R72.htm	Edgar Link	pending
R73.htm	Edgar Link	pending
R74.htm	Edgar Link	pending
R75.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
sibn-20181231.xml	Edgar Link	completed
sibn-20181231.xsd	Edgar Link	pending
sibn-20181231_cal.xml	Edgar Link	unprocessable
sibn-20181231_def.xml	Edgar Link	unprocessable
sibn-20181231_lab.xml	Edgar Link	unprocessable
sibn-20181231_pre.xml	Edgar Link	unprocessable
sibn-ex211_listxofxsubsidi.htm	Edgar Link	pending
sibn-ex231_pwcxconsent.htm	Edgar Link	pending
sibn-ex311_12311810xk.htm	Edgar Link	pending
sibn-ex312_12311810xk.htm	Edgar Link	pending
sibn-ex321_12311810xk.htm	Edgar Link	pending
sibn1231201810-k.htm	Edgar Link	pending
waterfallchartasof12312018je.jpg	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$SIBN
SI-BONE Inc Stock $sibn

2019 Q1 Form 10-K Financial Statement

#000145983919000011 Filed on March 14, 2019

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$SIBN SI-BONE Inc Stock $sibn

2019 Q1 Form 10-K Financial Statement

#000145983919000011 Filed on March 14, 2019

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$SIBN
SI-BONE Inc Stock $sibn